1. Powers HJ. Riboflavin (vitamin B-2) and health. Am J Clin Nutr 77: 1352-60, 2003.
2. Depeint F, Bruce WR, Shangari N, Mehta R, and O'Brien PJ. Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism. Chem Biol Interact 163: 94-112, 2006.
3 Balasubramaniam S, Christodoulou J, and Rahman S. Disorders of riboflavin metabolism. J Inherit Metab Dis 42: 608-19, 2019.
4. HORWITT MK, HARVEY CC, HILLS OW, and LIEBERT E. Correlation of urinary excretion of riboflavin with dietary intake and symptoms of ariboflavinosis. J Nutr 41: 247- 64, 1950.
5. Thakur K, Tomar SK, Singh AK, Mandal S, and Arora S. Riboflavin and health: A review of recent human research. Crit Rev Food Sci Nutr 57: 3650-60, 2017.
6. Foraker AB, Khantwal CM, and Swaan PW. Current perspectives on the cellular uptake and trafficking of riboflavin. Adv Drug Deliv Rev 55: 1467-83, 2003.
7. Yonezawa A, and Inui K. Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. Mol Aspects Med 34: 693-701, 2013.
8. Yonezawa A, Masuda S, Katsura T, and Inui K. Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am J Physiol Cell Physiol 295: C632- 41, 2008.
9. Yao Y, Yonezawa A, Yoshimatsu H, Masuda S, Katsura T, and Inui K. Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J Nutr 140: 1220-6, 2010.
10. Yamamoto S, Inoue K, Ohta KY, Fukatsu R, Maeda JY, Yoshida Y, and Yuasa H. Identification and functional characterization of rat riboflavin transporter 2. J Biochem 145: 437-43, 2009.
11. Yoshimatsu H, Yonezawa A, Yao Y, Sugano K, Nakagawa S, Omura T, and Matsubara K. Functional involvement of RFVT3/SLC52A3 in intestinal riboflavin absorption. Am J Physiol Gastrointest Liver Physiol 306: G102-10, 2014.
12. Bosch AM, Abeling NG, Ijlst L, Knoester H, van der Pol WL, Stroomer AE, Wanders RJ, Visser G, Wijburg FA, Duran M, and Waterham HR. Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment. J Inherit Metab Dis 34: 159-64, 2011.
13. O'Callaghan B, Bosch AM, and Houlden H. An update on the genetics, clinical presentation, and pathomechanisms of human riboflavin transporter deficiency. J Inherit Metab Dis 42: 598-607, 2019.
14. Green P, Wiseman M, Crow YJ, Houlden H, Riphagen S, Lin JP, Raymond FL, Childs AM, Sheridan E, Edwards S, and Josifova DJ. Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54. Am J Hum Genet 86: 485-9, 2010.
15. Ciccolella M, Corti S, Catteruccia M, Petrini S, Tozzi G, Rizza T, Carrozzo R, Nizzardo M, Bordoni A, Ronchi D, D'Amico A, Rizzo C, Comi GP, and Bertini E. Riboflavin transporter 3 involvement in infantile Brown-Vialetto-Van Laere disease: two novel mutations. J Med Genet 50: 104-7, 2013.
16. Jaeger B, and Bosch AM. Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience. J Inherit Metab Dis 39: 559-64, 2016.
17. Khadilkar SV, Faldu HD, Udani V, Patil SB, and Malvadkar S. Reversible posterior column dysfunction in Brown-Vialetto-Von Laere syndrome. Muscle Nerve 56: E28-E31, 2017.
18. Manole A, Jaunmuktane Z, Hargreaves I, Ludtmann MHR, Salpietro V, Bello OD, Pope S, Pandraud A, Horga A, Scalco RS, Li A, Ashokkumar B, Lourenço CM, Heales S, Horvath R, Chinnery PF, Toro C, Singleton AB, Jacques TS, Abramov AY, Muntoni F, Hanna MG, Reilly MM, Revesz T, Kullmann DM, Jepson JEC, and Houlden H. Clinical, pathological and functional characterization of riboflavin-responsive neuropathy. Brain 140: 2820-37, 2017.
19. Gayathri S, Gowda VK, Udhayabanu T, O'Callaghan B, Efthymiou S, Varalakshmi P, Benakappa N, Houlden H, and Ashokkumar B. Brown-Vialetto-Van Laere and Fazio-Londe syndromes: SLC52A3 mutations with puzzling phenotypes and inheritance. Eur J Neurol, 2020.
20. Dezfouli MA, Yadegari S, Nafissi S, and Elahi E. Four novel C20orf54 mutations identified in Brown-Vialetto-Van Laere syndrome patients. J Hum Genet 57: 613-7, 2012.
21. Johnson JO, Gibbs JR, Megarbane A, Urtizberea JA, Hernandez DG, Foley AR, Arepalli S, Pandraud A, Simón-Sánchez J, Clayton P, Reilly MM, Muntoni F, Abramzon Y, Houlden H, and Singleton AB. Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease. Brain 135: 2875-82, 2012.
22. Thulasi V, Veerapandiyan A, Pletcher BA, Tong CM, and Ming X. A case of Brown-Vialetto- Van Laere Syndrome due to a novel mutation in. Child Neurol Open 4: 2329048X17725610, 2017.
23. Hossain MA, Obaid A, Rifai M, Alem H, Hazwani T, Al Shehri A, Alfadhel M, Eto Y, and Eyaid W. Early onset of Fazio-Londe syndrome: the first case report from the Arabian Peninsula. Hum Genome Var 4: 17018, 2017.
24. Chaya S, Zampoli M, Gray D, Booth J, Riordan G, Ndondo A, Fieggen K, Rusch J, van der Watt G, Pillay K, van der Westhuizen F, Menezes M, and Wilmshurst J. The First Case of Riboflavin Transporter Deficiency in sub-Saharan Africa. Semin Pediatr Neurol 26: 10-4, 2018.
25. Gowda VK, Udhayabanu T, Varalakshmi P, Srinivasan VM, and Ashokkumar B. Fazio-Londe syndrome in siblings from India with different phenotypes. Brain Dev 40: 582-6, 2018.
26. Camargos S, Guerreiro R, Bras J, and Mageste LS. Late-onset and acute presentation of Brown-Vialetto-Van Laere syndrome in a Brazilian family. Neurol Genet 4: e215, 2018.
27. Foley AR, Menezes MP, Pandraud A, Gonzalez MA, Al-Odaib A, Abrams AJ, Sugano K, Yonezawa A, Manzur AY, Burns J, Hughes I, McCullagh BG, Jungbluth H, Lim MJ, Lin JP, Megarbane A, Urtizberea JA, Shah AH, Antony J, Webster R, Broomfield A, Ng J, Mathew AA, O'Byrne JJ, Forman E, Scoto M, Prasad M, O'Brien K, Olpin S, Oppenheim M, Hargreaves I, Land JM, Wang MX, Carpenter K, Horvath R, Straub V, Lek M, Gold W, Farrell MO, Brandner S, Phadke R, Matsubara K, McGarvey ML, Scherer SS, Baxter PS, King MD, Clayton P, Rahman S, Reilly MM, Ouvrier RA, Christodoulou J, Züchner S, Muntoni F, and Houlden H. Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain 137: 44-56, 2014.
28. Allison T, Roncero I, Forsyth R, Coffman K, and Pichon JL. Brown-Vialetto-Van Laere Syndrome as a Mimic of Neuroimmune Disorders: 3 Cases From the Clinic and Review of the Literature. J Child Neurol 32: 528-32, 2017.
29. Shi K, Shi Z, Yan H, Wang X, Yang Y, Xiong H, Gu Q, Wu Y, Jiang Y, and Wang J. A Chinese pedigree with Brown-Vialetto-Van Laere syndrome due to two novel mutations of SLC52A2 gene: clinical course and response to riboflavin. BMC Med Genet 20: 76, 2019.
30. Amir F, Atzinger C, Massey K, Greinwald J, Hunter LL, Ulm E, and Kettler M. The Clinical Journey of Patients with Riboflavin Transporter Deficiency Type 2. J Child Neurol 35: 283- 90, 2020.
31. Carreau C, Benoit C, Ahle G, Cauquil C, Roubertie A, Lenglet T, Cosgrove J, Meunier I, Veauville-Merllié A, Acquaviva-Bourdain C, and Nadjar Y. Late-onset riboflavin transporter deficiency: a treatable mimic of various motor neuropathy aetiologies. J Neurol Neurosurg Psychiatry 0: 1-9, 2020.
32. Kranthi P, Garuda BR, Gopi S, and Kumar TS. Brown-Vialetto-Van Laere syndrome: A rare case report of MND mimic. Neurol India 68: 1217-9, 2020.
33. Carreau C, Lenglet T, Mosnier I, Lahlou G, Fargeot G, Weiss N, Demeret S, Salachas F, Veauville-Merllié A, Acquaviva C, and Nadjar Y. A juvenile ALS-like phenotype dramatically improved after high-dose riboflavin treatment. Ann Clin Transl Neurol 7: 250-3, 2020.
34. Fan J, and Fogel BL. Successful treatment of a genetic childhood ataxia due to riboflavin transporter deficiency. Cerebellum Ataxias 5: 12, 2018.
35. Garg M, Kulkarni SD, Hegde AU, and Shah KN. Riboflavin Treatment in Genetically Proven Brown-Vialetto-Van Laere Syndrome. J Pediatr Neurosci 13: 471-3, 2018.
36. Menezes MP, Farrar MA, Webster R, Antony J, O'Brien K, Ouvrier R, Kiernan MC, Burns J, and Vucic S. Pathophysiology of motor dysfunction in a childhood motor neuron disease caused by mutations in the riboflavin transporter. Clin Neurophysiol 127: 911-8, 2016a.
37. Menezes MP, O'Brien K, Hill M, Webster R, Antony J, Ouvrier R, Birman C, and Gardner- Berry K. Auditory neuropathy in Brown-Vialetto-Van Laere syndrome due to riboflavin transporter RFVT2 deficiency. Dev Med Child Neurol 58: 848-54, 2016b.
38. Anand G, Hasan N, Jayapal S, Huma Z, Ali T, Hull J, Blair E, McShane T, and Jayawant S. Early use of high-dose riboflavin in a case of Brown-Vialetto-Van Laere syndrome. Dev Med Child Neurol 54: 187-9, 2012.
39. Koy A, Pillekamp F, Hoehn T, Waterham H, Klee D, Mayatepek E, and Assmann B. Brown- Vialetto-Van Laere syndrome: a riboflavin-unresponsive patient with a novel mutation in the C20orf54 gene. Pediatr Neurol 46: 407-9, 2012.
40. Bashford JA, Chowdhury FA, and Shaw CE. Remarkable motor recovery after riboflavin therapy in adult-onset Brown-Vialetto-Van Laere syndrome. Pract Neurol 17: 53-6, 2017.
41. Pillai NR, Amin H, Gijavanekar C, Liu N, Issaq N, Broniowska KA, Bertuch AA, Sutton VR, Elsea SH, and Scaglia F. Hematologic presentation and the role of untargeted metabolomics analysis in monitoring treatment for riboflavin transporter deficiency. Am J Med Genet A 182: 2781-7, 2020.
42. Bosch AM, Stroek K, Abeling NG, Waterham HR, Ijlst L, and Wanders RJ. The Brown- Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives. Orphanet J Rare Dis 7: 83, 2012.
43. Woodcock IR, Menezes MP, Coleman L, Yaplito-Lee J, Peters H, White SM, Stapleton R, Phelan DG, Chong B, Lunke S, Stark Z, Pitt J, Ryan MM, Robertson C, and Yiu EM. Genetic, Radiologic, and Clinical Variability in Brown-Vialetto-van Laere Syndrome. Semin Pediatr Neurol 26: 2-9, 2018.
44. Levy G, and Jusko WJ. Factors affecting the absorption of riboflavin in man. J Pharm Sci 55: 285-9, 1966.
45. Jusko WJ, and Levy G. Absorption, metabolism, and excretion of riboflavin-5'-phosphate in man. J Pharm Sci 56: 58-62, 1967.
46. Daniel H, Wille U, and Rehner G. In vitro kinetics of the intestinal transport of riboflavin in rats. J Nutr 113: 636-43, 1983.
47. Said HM, and Arianas P. Transport of riboflavin in human intestinal brush border membrane vesicles. Gastroenterology 100: 82-8, 1991.
48. Yoshimatsu H, Yonezawa A, Yamanishi K, Yao Y, Sugano K, Nakagawa S, Imai S, Omura T, Nakagawa T, Yano I, Masuda S, Inui K, and Matsubara K. Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice. Sci Rep 6: 27557, 2016.
49. Pinto JT, and Zempleni J. Riboflavin. Adv Nutr 7: 973-5, 2016.
50. Rivlin RS. Riboflavin metabolism. N Engl J Med 283: 463-72, 1970.
51. Akiyama T, Selhub J, and Rosenberg IH. FMN phosphatase and FAD pyrophosphatase in rat intestinal brush borders: role in intestinal absorption of dietary riboflavin. J Nutr 112: 263-8, 1982.
52. Yao Y, Yonezawa A, Yoshimatsu H, Omura T, Masuda S, and Matsubara K. Involvement of riboflavin transporter RFVT2/Slc52a2 in hepatic homeostasis of riboflavin in mice. Eur J Pharmacol 714: 281-7, 2013.
53. Ogunleye AJ, and Odutuga AA. The effect of riboflavin deficiency on cerebrum and cerebellum of developing rat brain. J Nutr Sci Vitaminol (Tokyo) 35: 193-7, 1989.
54. Rizzo F, Ramirez A, Compagnucci C, Salani S, Melzi V, Bordoni A, Fortunato F, Niceforo A, Bresolin N, Comi GP, Bertini E, Nizzardo M, and Corti S. Genome-wide RNA-seq of iPSC- derived motor neurons indicates selective cytoskeletal perturbation in Brown-Vialetto disease that is partially rescued by riboflavin. Sci Rep 7: 46271, 2017.
55. Greig LC, Woodworth MB, Galazo MJ, Padmanabhan H, and Macklis JD. Molecular logic of neocortical projection neuron specification, development and diversity. Nat Rev Neurosci 14: 755-69, 2013.
56. Englund C, Fink A, Lau C, Pham D, Daza RA, Bulfone A, Kowalczyk T, and Hevner RF. Pax6, Tbr2, and Tbr1 are expressed sequentially by radial glia, intermediate progenitor cells, and postmitotic neurons in developing neocortex. J Neurosci 25: 247-51, 2005.
57. Hevner RF. Intermediate progenitors and Tbr2 in cortical development. J Anat 235: 616-625, 2019.
58. Spagnoli C, Pitt MC, Rahman S, and de Sousa C. Brown-Vialetto-van Laere syndrome: a riboflavin responsive neuronopathy of infancy with singular features. Eur J Paediatr Neurol 18: 231-4, 2014.
59. Nimmo GAM, Ejaz R, Cordeiro D, Kannu P, and Mercimek-Andrews S. Riboflavin transporter deficiency mimicking mitochondrial myopathy caused by complex II deficiency. Am J Med Genet A 176: 399-403, 2018.
60. Ciccolella M, Catteruccia M, Benedetti S, Moroni I, Uziel G, Pantaleoni C, Chiapparini L, Bizzi A, D'Amico A, Fattori F, Salsano ML, Pastore A, Tozzi G, Piemonte F, and Bertini E. Brown-Vialetto-van Laere and Fazio-Londe overlap syndromes: a clinical, biochemical and genetic study. Neuromuscul Disord 22: 1075-82, 2012.
61. Powers HJ, Corfe BM, and Nakano E. Riboflavin in development and cell fate. Subcell Biochem 56: 229-45, 2012.
62. Guissart C, Drouot N, Oncel I, Leheup B, Gershoni-Barush R, Muller J, Ferdinandusse S, Larrieu L, Anheim M, Arslan EA, Claustres M, Tranchant C, Topaloglu H, and Koenig M. Genes for spinocerebellar ataxia with blindness and deafness (SCABD/SCAR3, MIM# 271250 and SCABD2). Eur J Hum Genet 24: 1154-9, 2016.
63. Srour M, Putorti ML, Schwartzentruber J, Bolduc V, Shevell MI, Poulin C, O'ferrall E, Buhas D, Majewski J, Brais B, and Consortium FC. Mutations in riboflavin transporter present with severe sensory loss and deafness in childhood. Muscle Nerve 50: 775-9, 2014.
64. Brunskill EW, Potter AS, Distasio A, Dexheimer P, Plassard A, Aronow BJ, and Potter SS. A gene expression atlas of early craniofacial development. Dev Biol 391: 133-46, 2014.
65. Haack TB, Makowski C, Yao Y, Graf E, Hempel M, Wieland T, Tauer U, Ahting U, Mayr JA, Freisinger P, Yoshimatsu H, Inui K, Strom TM, Meitinger T, Yonezawa A, and Prokisch H. Impaired riboflavin transport due to missense mutations in SLC52A2 causes Brown-Vialetto- Van Laere syndrome. J Inherit Metab Dis 35: 943-8, 2012.
66. Nabokina SM, Subramanian VS, and Said HM. Effect of clinical mutations on functionality of the human riboflavin transporter-2 (hRFT-2). Mol Genet Metab 105: 652-7, 2012.
67. Udhayabanu T, Subramanian VS, Teafatiller T, Gowda VK, Raghavan VS, Varalakshmi P, Said HM, and Ashokkumar B. SLC52A2 [p.P141T] and SLC52A3 [p.N21S] causing Brown- Vialetto-Van Laere Syndrome in an Indian patient: First genetically proven case with mutations in two riboflavin transporters. Clin Chim Acta 462: 210-214, 2016.
68. Collins FS, Rossant J, and Wurst W. A mouse for all reasons. Cell 128: 9-13, 2007.
69. Cardiff RD, Miller CH, and Munn RJ. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc 2014: 655-8, 2014.
70. Silver DL, Watkins-Chow DE, Schreck KC, Pierfelice TJ, Larson DM, Burnetti AJ, Liaw HJ, Myung K, Walsh CA, Gaiano N, and Pavan WJ. The exon junction complex component Magoh controls brain size by regulating neural stem cell division. Nat Neurosci 13: 551-8, 2010.
71. Nishihara K, Masuda S, Nakagawa S, Yonezawa A, Ichimura T, Bonventre JV, and Inui K. Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats. Am J Physiol Renal Physiol 298: F923-34, 2010.